GSK (NYSE:GSK) Shares Gap Up – Here’s What Happened

GSK PLC Sponsored ADR (NYSE:GSK)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $48.13, but opened at $50.29. GSK shares last traded at $49.73, with a volume of 744,536 shares.

More GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK reported positive Phase III overall-survival data for its Ris‑Rez program in relapsed small-cell lung cancer in China. The treatment reportedly reduced the risk of death by 54% and met the trial’s primary endpoint, potentially supporting future regulatory filings and adding a meaningful oncology growth opportunity. GSK PLC Announces Positive Phase III Overall Survival Data
• Positive Sentiment: Additional coverage highlighted a 94% response rate and a successful late-stage trial for GSK’s potential small-cell lung cancer drug, reinforcing expectations that the program could become an important pipeline asset. GSK Reports 94% Response Rate for Lung Cancer Drug Trial
• Positive Sentiment: GSK plans to expand its U.S. submission for Jideytro following positive results, while separate reports cited efficacy when the drug was used in earlier-line treatment. A broader label or earlier use could increase the medicine’s commercial potential if regulators accept the data. GSK Plans Expanded US Submission for Jideytro
• Positive Sentiment: GSK characterized the Ris‑Rez and Jideytro updates as evidence of pipeline momentum, which may help offset investor concerns about long-term pharmaceutical growth and patent exposure. GSK Highlights Pipeline Momentum
• Neutral Sentiment: GSK also discussed using health data from the Greater Bay Area to improve healthcare policy. The initiative may support research and regional relationships but is unlikely to materially affect near-term earnings. Greater Bay Area Healthcare Policy Data

Analysts Set New Price Targets

Several brokerages have issued reports on GSK. Citigroup began coverage on GSK in a research report on Friday, July 24th. They set a “neutral” rating on the stock. Royal Bank Of Canada started coverage on GSK in a research note on Tuesday, September 8th. They set a “sector perform” rating for the company. Wall Street Zen downgraded GSK from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Morgan Stanley reiterated an “underweight” rating on shares of GSK in a research note on Tuesday, August 25th. Finally, Weiss Ratings downgraded shares of GSK from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $53.00.

GSK Stock Up 3.5%

The company’s fifty day simple moving average is $51.29 and its 200-day simple moving average is $52.75. The firm has a market capitalization of $100.80 billion, a PE ratio of 15.59, a price-to-earnings-growth ratio of 2.02 and a beta of 0.35. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52.

GSK (NYSE:GSK) last issued its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.27 by $0.09. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.02 billion. GSK had a return on equity of 43.23% and a net margin of 14.56%.The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.47 EPS. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, analysts forecast that GSK PLC Sponsored ADR will post 4.81 EPS for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 8th. Investors of record on Friday, August 14th will be given a dividend of $0.4515 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $1.81 annualized dividend and a yield of 3.6%. This is an increase from GSK’s previous quarterly dividend of $0.44. GSK’s dividend payout ratio is currently 55.63%.

Institutional Investors Weigh In On GSK

Several institutional investors have recently added to or reduced their stakes in the business. Fisher Asset Management LLC lifted its holdings in shares of GSK by 3.0% during the fourth quarter. Fisher Asset Management LLC now owns 33,195,985 shares of the pharmaceutical company’s stock worth $1,627,931,000 after purchasing an additional 968,370 shares during the period. NewEdge Advisors LLC raised its position in GSK by 842.9% during the 2nd quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock worth $49,986,000 after buying an additional 852,437 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S raised its position in GSK by 2,032.8% during the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 854,331 shares of the pharmaceutical company’s stock worth $41,896,000 after buying an additional 814,275 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in GSK by 1.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 401,777 shares of the pharmaceutical company’s stock valued at $15,444,000 after acquiring an additional 4,855 shares during the period. Finally, Waverly Advisors LLC lifted its stake in GSK by 1,372.8% during the 2nd quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company’s stock valued at $15,233,000 after acquiring an additional 270,863 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

About GSK

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.